Veridiana Pires de Camargo

Veridiana Pires de Camargo

Auto-generated profile, based on publicly available information

Veridiana Pires de Camargo

Latin American Cooperative Oncology Group, Porto Alegre, Brazil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2022 in Cancer
Verified
Journal Article
Closed access
RMRodrigo R. Munhoz
Rodrigo R. Munhoz
GNGuilherme Nader‐Marta
Guilherme Nader‐Marta
VCVeridiana P. de Camargo
Veridiana P. de Camargo
MQMarcello M. Queiroz
Marcello M. Queiroz
JCJade Cury‐Martins
Jade Cury‐Martins
GCGilberto de Castro
Gilberto de Castro

1 March 2019 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
JCJuliana Arcangelo Di Vita Carvalho
Juliana Arcangelo Di Vita Carvalho
CBCaroline Chaul de Lima Barbosa
Caroline Chaul de Lima Barbosa
OFOlavo Feher
Olavo Feher
MMMarcos Vinicius Calfat Maldaun
Marcos Vinicius Calfat Maldaun
VCVeridiana Pires de Camargo
Veridiana Pires de Camargo
GMGustavo Marta
Gustavo Marta
SUMMARY INTRODUCTION: Glioblastoma (GBM) is the most frequent primary malignant tumor from the central nervous system in adults. However, the presence of systemic metastasis is an extremely rare event. The objective of this study was to review the literature, evaluating the possible biological mechanisms related to the occurrence of systemic metastasis in patients diagnosed with GBM. RESULTS: The mechanisms that may be related to GBM systemic dissemination are the blood-brain barrier breach, often seen in GBM cases, by the tumor itself or by surgical procedures, gaining access to blood and lymphatic vessels, associated with the acquisition of mesenchymal features of invasiveness, resistance to the immune mechanisms of defense and hostile environment through quiescence. CONCLUSIONS: Tumor cells must overcome many obstacles until the development of systemic metastasis. The physiologic mechanisms are not completely clear. Although not fully understood, the pathophysiological understanding of the mechanisms that may be associated with the systemic spread is salutary for a global understanding of the disease. In addition, this knowledge may be used as a basis for a therapy to be performed in patients diagnosed with GBM distant metastasis.

1 November 2020 in JCO Global Oncology
Verified
Journal Article
Open access
NGNader Marta Guilherme
Nader Marta Guilherme
RMRodrigo Ramella Munhoz
Rodrigo Ramella Munhoz
MTMonica La Porte Teixeira
Monica La Porte Teixeira
BWBernadette Cunha Waldvogel
Bernadette Cunha Waldvogel
VCVeridiana Pires de Camargo
Veridiana Pires de Camargo
JSJose Antonio Sanches
Jose Antonio Sanches
PURPOSE: A substantial increase in melanoma incidence has been consistently observed worldwide over the past decades. However, melanoma mortality rates have remained stable or declined over the past years in most regions. Given the paucity of melanoma mortality data for different Brazilian regions, we sought to describe melanoma mortality trends in southeastern Brazil and their relationship with demographic variables. MATERIALS AND METHODS: A cross-sectional registry-based analysis was conducted to describe melanoma mortality trends in the state of São Paulo, Brazil, from 1996 to 2016. Demographic information from melanoma-related death records, including sex and age, was collected from the Fundação Sistema Estadual de Análise de Dados database. The annual percentage change (APC) was calculated to identify mortality trends over the period. RESULTS: An increasing melanoma mortality trend was detected among males, regardless of age (APC, 1.72%; P < .001), and was more pronounced for men ≥ 60 years old (APC, 2.63%; P < .001). Melanoma mortality rates have also increased for patients ≥ 60 years old, regardless of sex (APC, 1.11%; P < .001). A non–statistically significant increase in the overall melanoma mortality rate was observed over the 20-year period analyzed (APC, 0.36%; P = .4). CONCLUSION: Our data suggest a stable melanoma mortality over the past two decades for the overall population studied; however, a significant increase in melanoma mortality rates has been demonstrated among males and in the population ≥ 60 years old, emphasizing the need to implement prevention strategies and expand access to effective therapies for this population.

1 February 2021 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
GBGabriel Novaes de Rezende Batistella
Gabriel Novaes de Rezende Batistella
ASAdrialdo José Santos
Adrialdo José Santos
MNManoel Antonio de Paiva Neto
Manoel Antonio de Paiva Neto
RFRobson Ferrigno
Robson Ferrigno
VCVeridiana Pires de Camargo
Veridiana Pires de Camargo
MMMarcos Vinicius Calfat Maldaun
Marcos Vinicius Calfat Maldaun
Background: Cancer patients in general and glioblastoma patients, in particular, have an increased risk of developing complications from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and reaching a balance between the risk of exposure to infection and the clinical benefit of their treatment is ideal. The aggressive behavior of this group of tumors justifies the need for a multidisciplinary team to assist in clinical decisions during the current pandemic. Brazil is now ranked #2 in the number of cases and deaths from COVID-19 pandemic, and existing disparities in the treatment of neuro-oncology patients in Brazil will challenge the clinical and surgical decisions of this population, possibly affecting global survival. Objective: To search the literature about the management of glioblastomas during COVID-19 pandemic to guide surgical and clinical decisions in this population of patients in Brazil. Methods: We performed a systematic search on the PubMed electronic database targeting consensus statements concerning glioblastoma approaches during COVID-19 pandemic up to July 18, 2020. Results: When approaching glioblastoma during the COVID-19 pandemic, important parameters that help in the decision-making process are age, performance status, tumor molecular profile, and patient consent. Younger patients should follow the standard protocol after maximal safe resection, mainly those with MGMT methylated tumors. Aged and underperforming patients should be carefully evaluated, and probably a monotherapy scheme is to be considered. Centers are advised to engage in telemedicine and to elaborate means to reduce local infection. Conclusion: Approaching glioblastoma during the COVID-19 pandemic will be challenging worldwide, but particularly in Brazil, where a significant inequality of healthcare exists.

1 September 2021 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
RMR. Ramella Munhoz
R. Ramella Munhoz
VCV.P. de Camargo
V.P. de Camargo
NGNader Marta Guilherme
Nader Marta Guilherme
MQM.M. Queiroz
M.M. Queiroz
JCJ. Cury-Martins
J. Cury-Martins
GCG. de Castro
G. de Castro

1 January 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
DSDouglas Dias e Silva
Douglas Dias e Silva
BDBruna Bianca Lopes David
Bruna Bianca Lopes David
VCVeridiana Pires de Camargo
Veridiana Pires de Camargo
RFRenee Zon Filipi
Renee Zon Filipi
MDMaría Lucila González Donna
María Lucila González Donna
RPRoberto Carmagnani Pestana
Roberto Carmagnani Pestana
PURPOSE: The availability of drugs and national public policies for patients with rare cancers, including sarcomas, varies in different parts of the world. METHODS: In this manuscript, we have conducted a comprehensive analysis to evaluate rare cancer policies in Latin American countries' national policy documents. Additionally, we have reviewed the approvals for sarcoma drugs in selected Latin American countries and compared them with US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals. RESULTS: The documents reviewed showed a lack of explicit focus on rare cancers, with no mention in 70% of the countries analyzed. Drug approval data reveal that in the last 15 years, the FDA and EMA have approved 19 and 13 drugs for sarcoma, whereas their Latin American counterparts, namely ANVISA, ANMAT, and COFEPRIS, approved six, eight, and seven drugs, respectively. CONCLUSION: Our data suggest that improving rare cancer and sarcoma care in Latin America requires enhanced collaboration for better rare cancer policies.